Ever since Biogen and Eisai’s Aduhelm (aducanemab) was approved in 2021 as the first antibody to treat Alzheimer’s disease by ...

Growing research shows common herpes viruses may raise dementia risk, challenging previous skepticism and opening new paths ...

There are two major proteins that have been associated with the disease, and recent years have seen something of a push-and-pull between scientists trying to determine which of the two, amyloid-β or ...

A few limited clinical trials of lithium for Alzheimer’s disease have shown some efficacy, but the lithium compounds they ...

Researchers at Boston University Chobanian & Avedisian School of Medicine have built an artificial intelligence (AI) tool ...

Besides delving more deeply into the PET-derived plaque measurements -- showing favorable effects in key brain regions, for example -- Klein also reported on amyloid-beta and tau protein ...

Voyager includes its wholly-owned Alzheimer’s disease programme to pipeline, complementing Tau and Amyloid assets with new APOE approach ...

In Alzheimer's disease, proteins like amyloid beta form clumps, known as plaques, that damage the brain.

- Voyager’s wholly-owned Alzheimer’s disease franchise now includes clinical-stage anti-tau antibody VY7523 as well as gene therapies targeting tau, amyloid, and APOE - ...

- New program combines IV-delivered TRACER™ capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the protective APOE2 variant - - Voyager’s ...